PDCD1 and cancer: However, only a small portion of patients with cancer achieve positive responses to ICIs, mainly, to inhibitors of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).